{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:51:27Z","timestamp":1788306687994,"version":"build-2803163510"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Eculizumab is a C5 complement inhibitor approved by the FDA for the targeted treatment of four rare diseases, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and aquaporin-4 immunoglobulin G-positive optic neuromyelitis optica spectrum disorders (AQP4-IgG+NMOSD). The current study was conducted to assess real-world adverse events (AEs) associated with eculizumab through data mining of the FDA Adverse Event Reporting System (FAERS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Disproportionality analyses, including Reporting Ratio Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-Item Gamma Poisson Shrinker (MGPS) algorithms were used to quantify the signals of eculizumab-associated AEs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 46,316 eculizumab-related ADEs reports were identified by analyzing 19,418,776 reports in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) database. A total of 461\u00a0PTs were identified as satisfying by all four algorithms. These PTs reported adverse reactions consistent with the specifications, such as fatigue, nasopharyngitis, meningococcal infection, fever, and anemia. Some PTs, such as aplastic anemia, gene mutation, mastication disorder, kidney fibrosis, BK virus infection, abnormal neutrophil count, C3 glomerulopathy, neuroblastoma, and glomerulonephritis membranoproliferative, were also detected outside the instructions. The median time to onset of eculizumab adverse events was 159\u00a0days (interquartile range [IQR] 11\u223c738\u00a0days). In addition, at the PT level, 51\u00a0PTs were determined to have an imbalance in the occurrence of ADEs between the sexes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings provide valuable insights into the occurrence of ADEs following the use of eculizumab and could support clinical monitoring and risk identification efforts.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2024.1440907","type":"journal-article","created":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T01:12:52Z","timestamp":1736385172000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Adverse drug events (ADEs) risk signal mining related to eculizumab based on the FARES database"],"prefix":"10.3389","volume":"15","author":[{"given":"Xi-Feng","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu-Ri","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ta-La","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui-Feng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wu-Niri","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Yuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Rong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen-Li","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Fang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous ADR reporting","volume":"18","author":"Bate","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1182\/blood.2020010234","article-title":"Eculizumab and aHUS: to stop or not","volume":"137","author":"Brodsky","year":"2021","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s40264-020-00911-w","article-title":"Disproportionality analysis for pharmacovigilance signal detection in small databases or subsets: recommendations for limiting false-positive associations","volume":"43","author":"Caster","year":"2020","journal-title":"Drug Saf."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1007\/s11255-022-03211-7","article-title":"Acute kidney injury following SGLT2 inhibitors among diabetic patients: a pharmacovigilance study","volume":"54","author":"Chen","year":"2022","journal-title":"Int. Urol. Nephrol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3969\/j.issn.2095-1264.2021.04.01","article-title":"Safety comparison of axitinib and everolimus in the treatment of renal cancer:analysis of adverse events based on pharmacovigilance database","volume":"11","author":"Chen","year":"2021","journal-title":"Anti-tumor Pharm."},{"key":"B6","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1093\/cid\/ciy958","article-title":"Disseminated gonococcal infections in patients receiving eculizumab: a case series","volume":"69","author":"Crew","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1259908","DOI":"10.3389\/fphar.2023.1259908","article-title":"A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say","volume":"14","author":"Cui","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1016\/j.bbmt.2018.07.032","article-title":"Eculizumab bridging before bone marrow transplant for marrow failure disorders is safe and does not limit engraftment","volume":"24","author":"DeZern","year":"2018","journal-title":"Biol. Blood Marrow Transpl."},{"key":"B9","first-page":"607","article-title":"The enlightens on Ca rrying out reporting responsibility of manufactures in China from reviewing the post ma rketing surveillance system in US","volume":"14","author":"Dong","year":"2017","journal-title":"Chin. J. Pharmacovigil."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1182\/blood.2020009280","article-title":"Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study","volume":"137","author":"Fakhouri","year":"2021","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","first-page":"892503","DOI":"10.3389\/fphar.2022.892503","article-title":"Development of a drug risk analysis and assessment system and its application in signal excavation and analysis of 263 cases of fluoroquinolone-induced adverse reactions","volume":"13","author":"Guan","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/jha2.632","article-title":"A phase III, randomised, double-blind, multi-national clinical trial comparing SB12 (proposed eculizumab biosimilar) and reference eculizumab in patients with paroxysmal nocturnal haemoglobinuria","volume":"4","author":"Jang","year":"2023","journal-title":"EJHaem"},{"key":"B14","doi-asserted-by":"publisher","first-page":"6786","DOI":"10.1182\/blood-2011-02-333997","article-title":"Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival","volume":"117","author":"Kelly","year":"2011","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","first-page":"D1373","DOI":"10.1093\/nar\/gkac956","article-title":"PubChem 2023 update","volume":"51","author":"Kim","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"293","DOI":"10.13286\/j.1001-5213.2022.03.12","article-title":"Literature analysis of non-infectious adverse reactions induced by eculizumab","volume":"42","author":"Li-li","year":"","journal-title":"Chin. J. Hosp. Pharm."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.13286\/j.1001-5213.2022.17.16","article-title":"Literature analysis of infectious adverse reactions induced by eculizumab","volume":"42","author":"Li-li","year":"","journal-title":"ChinJ HospPharm"},{"key":"B18","doi-asserted-by":"publisher","first-page":"734","DOI":"10.15585\/mmwr.mm6627e1","article-title":"High risk for invasive meningococcal disease among patients receiving eculizumab (Soliris) despite receipt of meningococcal vaccine","volume":"66","author":"McNamara","year":"2017","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.11477\/mf.1416200008","article-title":"C5: eculizumab","volume":"66","author":"Miyamoto","year":"2014","journal-title":"Brain Nerve"},{"key":"B20","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s12185-023-03630-x","article-title":"Real-world safety profile of eculizumab in patients with paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, or generalized myasthenia gravis: an integrated analysis of post-marketing surveillance in Japan","volume":"118","author":"Nishimura","year":"2023","journal-title":"Int. J. Hematol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/1744-9987.12763","article-title":"Atypical hemolytic-uremic syndrome: an update on pathophysiology, diagnosis, and treatment","volume":"23","author":"Raina","year":"2019","journal-title":"Ther. Apher. Dial."},{"key":"B22","first-page":"294","article-title":"Compa rative study on the common signal detection methods of adve rse drug reaction","volume":"8","author":"Ren","year":"2011","journal-title":"Chin. J. Pharmacovigil."},{"key":"B23","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/nrneph.2016.70","article-title":"Complement in disease: a defence system turning offensive","volume":"12","author":"Ricklin","year":"2016","journal-title":"Nat. Rev. Nephrol."},{"key":"B24","first-page":"19","article-title":"Pesg PNH diagnosis, follow-up and treatment guidelines","volume":"6","author":"Sahin","year":"2016","journal-title":"Am. J. Blood Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int. J. Med. Sci."},{"key":"B26","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s40620-018-0517-z","article-title":"Eculizumab in pregnancy: a narrative overview","volume":"32","author":"Sarno","year":"2019","journal-title":"J. Nephrol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s40264-015-0388-3","article-title":"Performance of stratified and subgrouped disproportionality analyses in spontaneous databases","volume":"39","author":"Seabroke","year":"2016","journal-title":"Drug Saf."},{"key":"B28","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/bjh.15790","article-title":"Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis","volume":"185","author":"Soci\u00e9","year":"2019","journal-title":"Br. J. Haematol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"139","DOI":"10.15932\/j.0253-9713.2020.02.013","article-title":"Advances in the diagnosis and treatment of atypical haemolytic uremic syndrome","volume":"42","author":"TianQi","year":"2020","journal-title":"BEIJING Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.beha.2008.02.005","article-title":"GVHD pathophysiology: is acute different from chronic","volume":"21","author":"Toubai","year":"2008","journal-title":"Best. Pract. Res. Clin. Haematol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"e103","DOI":"10.3324\/haematol.2017.182360","article-title":"Hematopoietic stem cell transplantation for patients with paroxysmal nocturnal hemoglobinuria previously treated with eculizumab: a retrospective study of 21 patients from SFGM-TC centers","volume":"103","author":"Vallet","year":"2018","journal-title":"Haematologica"},{"key":"B32","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3969\/j.issn.1672-5433.2015.10.005","article-title":"An introduction of American OpenFDA of public health Project","volume":"12","author":"Xu","year":"2015","journal-title":"China Licens. Pharm."},{"key":"B33","doi-asserted-by":"publisher","first-page":"975","DOI":"10.3870\/j.issn.1004-0781.2022.07.009","article-title":"Research on signal mining of adverse events of GLP-1 receptor agonists based on FAERS","volume":"41","author":"Yanxin","year":"2022","journal-title":"Her. Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"103828","DOI":"10.1016\/j.ajp.2023.103828","article-title":"Adverse events of epidiolex: a real-world drug safety surveillance study based on the FDA adverse event reporting system (FAERS) database","volume":"90","author":"Zhou","year":"2023","journal-title":"Asian J. Psychiatr."},{"key":"B35","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1159\/000248311","article-title":"Gender-based differences in drug prescription: relation to adverse drug reactions","volume":"84","author":"Zopf","year":"2009","journal-title":"Pharmacology"}],"updated-by":[{"DOI":"10.3389\/fphar.2025.1558930","type":"corrigendum","label":"Corrigendum","source":"publisher","updated":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000}}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1440907\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T06:32:39Z","timestamp":1738909959000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1440907\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,9]]},"references-count":35,"alternative-id":["10.3389\/fphar.2024.1440907"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1440907","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,9]]},"article-number":"1440907"}}